New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating significant effects in managing excess mass and diabetes second-type condition. Initial data suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/